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Abstract 
 
Background: Chitosan oligosaccharide, the degradation products of chitin, was reported to have a wide range of 
physiological functions and biological activities. In this study, we explored the inhibitory effect of Chitosan 
oligosaccharide on human hepatoma cells  
Materials and Methods: MTT assay was applied to detect cell viability of the human hepatoma cells treated with 
Chitosan oligosaccharide. Flow cytometric analysis was used to investigate the apoptosis of the human hepatoma cells 
treated with Chitosan oligosaccharide. We employed western blot to investigate the underlying mechanisms involved in 
the apoptosis. 
Results: Our data indicated that chitosan oligosaccharide dose-dependently inhibited the growth of hepatoma cells and 
induced apoptosis. On the molecular level, chitosan oligosaccharide decreased Bcl-2 and increased Caspase-3 
expression which may be related to the apoptosis of hepatoma cells.  
Conclusion: Our results provide an experimental basis for the clinical development of Chitosan oligosaccharide as a 
novel anti-hepatoma drug. 
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Abbreviations: COS: Chitosan oligosaccharide, PI: Propidium iodide, ATCC: American Type Culture Collection, 
DMSO: Dimethyl suphoxide, 5-Fu: 5-Fluorouracil, MTT: 3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide, PBS: Phosphate buffered saline, SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
NC: Nitrocellulose membrane, RIPA: Radio Immunoprecipitation Assay, ECL: Esports Champion League 
SMMC-7721: Human hepatocellular carcinoma, ANOVA: Analysis of Variance. 
 
Introduction 
 
Hepatoma is a common malignancy and its incidence is recently rising in the developing world. More than 
700,000 new cases are diagnosed throughout the world and more than 600,000 deaths are due to hepatoma each year 
(Renumathy et al., 2012). Conservative chemotherapy is not efficient for hepatoma patients because of drug resistance 
and toxic side effects (Meng et al., 2012). Therefore, it is urgent to find a novel therapeutic drug. 
Chitosan oligosaccharide (COS), obtained by hydrolysis or degradation of chitin (Xu et al., 2007), has 3-10 
saccharide (N-acetyl-glucosamine or glucosamine) residues (Han et al., 2005). Crustacean shells rich with Chitosan 
oligosaccharide have been used in Chinese medicine for long period. Studies indicated that chitosan oligosaccharide 
has a wide range of biological activities such as immunity regulation, anti-tumor, antioxidant and liver protection (Yin 
et al., 2009; Chakrabarti et al., 2004). However, the inhibition effect of chitosan oligosaccharide on hepatoma was 
rarely reported.  
The aim of this study was to explore the inhibition effect of chitosan oligosaccharide and the underlying 
mechanisms on hepatoma cells. Our study will provide an experimental basis for the clinical development of novel 
anti-hepatoma drug. 
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Materials and Methods 
Cell culture 
 
SMMC-7721 cells were obtained from ATCC. The cells were cultured in RPMI-1640 medium supplemented with 
10% fetal calf serum at 37 ℃. 
 
MTT assays 
  
The cells（4×104/well ) were plated in 96-cell plates. After treated with COS (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5 and 4.0 
mg/ml) for 24 h and 48 h, the viability of the cancer cells was detected by MTT assay. PBS (20 μl) and 5-Fluorouracil 
(5-Fu) (0.5 mg/ml) were added as the negative control and the positive control, respectively. Each concentration of 
COS was repeated in six wells. The cells were cultured for 24 h and 48 h and incubated with 20 μl MTT solution (5 
mg/ml) for 4 h. The formazan crystals were dissolved in 150 μl DMSO and the absorbance at 589 nm was determined 
with a Multiskan Ascent plate reader. 
 
Hoechst 33258 fluorescent staining to detect apoptosis 
 
The cells (1.5×105/well) were seeded into 6-well plate. After 24 h COS (2.5 mg/ml) treatment, the cells were fixed 
in 1 ml of 4% (V/V) formaldehyde at 4 ℃ for 10 min. Then 1 ml staining solution of Hoechst 33258 was added into 
each well and was kept in dark for 10 min at room temperature. The cells were observed at the wavelength of 340 nm 
by a fluorescence microscopy. 
 
Cell apoptosis by flow cytometry  
 
The cells (1.5×105/well) were seeded into 6-well plate. After 24 h COS (2.5 mg/ml) treatment, the cells were 
harvested and washed by PBS. Then the cells were stained with Annexin-V and PI solution for 10 min in dark and 
analyzed by flow cytometry. 
 
Western blot analysis 
 
The cells were harvested and solubilized in cold RIPA buffer. Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose (NC) membranes by semi-dry apparatus for 40 min and then blocked with blocking buffer 
for 1 h. The specific primary antibody 1:500 at optimized dilution was added and incubated overnight at 4 ℃. After 
incubation with secondary antibody 1:3000 for 2 h, protein bands were visualized by ECL kit. 
 
Statistical analysis 
 
Data were expressed as the mean ± SD. Data are expressed as the mean ± SD. All statistical analyses were 
performed with standard statistical programs SPSS 11.0. A one-way ANOVA was used for the statistical analysis. 
p<0.05 was considered to indicate a statistically significant difference. 
 
Results  
Effect of COS on proliferation of SMMC-7721 cell  
 
To evaluate the effect of COS on the growth of hepatoma, the MTT assay was performed. Our results showed that 
COS (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0 mg/ml) significantly inhibited the proliferation of SMMC-7721 cells 
(hepatoma cells) at low concentration groups (P<0.05). Hepatoma cancer cells treated with COS showed a reduced 
proliferation capacity in a dose-dependent manner (P<0.001). IC50 of COS on hepatoma cells for 24 h was 2.5 mg/ml 
(Figure 1).  
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Figure 1: Effect of COS on the proliferation of hepatoma cancer cells. SMMC-7721 cells were treated without or with 
different concentration of COS for 24 h and 48 h. The inhibition rate of the cell proliferation was examined by MTT 
assay and expressed using the equation: inhibiting rate(%) = (1-Abs test /Abs cont)×100%. “*” compared with negative 
control group, p < 0.05.  “**” compared with negative control group, p < 0.01. “***” compared with negative control 
group, p<0.001. 
 
Morphological changes observed by Hoechst 33258 fluorescent staining 
 
After the fluorescent dye Hoechst 33258 staining, SMMC-7721 cells showed weak blue fluorescence and 
distributed regularly. However with the COS treatment (2.5 mg/ml), the fluorescence intensity of SMMC-7721 cells 
became much stronger than the negative control group which indicating apparent apoptosis (Figure 2). 
 
Figure 2: SMMC-7721 cells Hoechst 33258 Fluorescent staining apoptotic morphology. SMMC-7721 cells were 
treated without or with COS (2.5 mg/ml) for 24 h and observed under the microscope (40 x). (A) SMMC-7721 cells 
treated without COS. (B) SMMC-7721 cells treated with COS. 
 
The effect of COS on the apoptosis of SMMC-7721cells 
 
The Annexin V/PI double staining results showed that SMMC-7721 cells of the negative control group were 
mainly distributed in the lower left quadrant (FITC-/PI-). However with COS treatment (2.5 mg/ml), the SMMC-7721 
cells were mainly distributed in the upper right quadrant (FITC+/PI+) and the late apoptotic cells increased up to 
76.04% (Figure 3). Our results indicated that the COS treatment could induce apoptosis on hepatoma cells.  
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Figure 3: The effect of COS on the apoptosis of SMMC-7721. SMMC-7721 cells were treated without or with COS 
(2.5 mg/ml) for 24 h and detected by flow cytometry. (A) SMMC-7721 cells were treated without COS. (B) 
SMMC-7721 cells were treated with COS. The early and late apoptosis cells were indicated by the lower right and 
upper right quadrants. 
 
The expression of Bcl-2 and Caspase-3 examined by Western blotting 
 
The increase of Bcl-2 expression can prevent the release of cytochrome c and thus caspase activation (Pinton et al., 
2000). Caspase-3 activation induces apoptosis via the cleavage of substrates known as mediators of apoptosis (Tanel et 
al., 2005). To further investigate the underlying molecular mechanism of COS on apoptosis, the expression of 
Caspase-3 and Bcl-2 were detected by Western blotting. Our western blotting results indicated that the expression of 
Cleaved-Caspase-3 and Bcl-2 were regulated in the COS treated SMMC-7721 cells (Figure 4). 
 
Figure 4.  Effect of COS on the expression of Bcl-2 and Caspase-3. SMMC-7721 cells were treated with COS (2.5 
mg/ml) for 24 h. The expression of Bcl-2 and Caspase-3 were detected by western-blotting. β-Actin served as loading 
control. The experiments were repeated three times.   
 
Discussion 
 
 Hepatoma is the seventh most common cancer and the third leading cause of cancer-related deaths in the world 
(Yang et al., 2010). This study aimed to explore inhibition effect of COS on hepatoma cells. The results demonstrated 
that low concentrations of COS significantly inhibited the growth of hepatoma cells and the inhibition rate increased 
with the concentration of COS increasing. In addition, low concentrations of COS induced apoptosis on hepatoma cells 
was related to down-regulated expression of Bcl-2 and up-regulated expression of Caspase-3. 
 Our data indicated that the low concentrations of COS significantly inhibited the proliferation of SMMC-7721 
cells (P<0.05). IC50 for SMMC-7721 cells at 24 h was 2.5 mg/ml. Previous study has showed that a 21-kDa 
water-soluble chitosan and oligochitosancan reduced the tumor growth in sarcoma 180-bearing mice which was similar 
with our results (Maeda et al., 2004).  
 We further investigated the underlying mechanisms of inhibiting effect of COS on the proliferation of hepatoma 
cells. The staining results and flow cytometry results both indicated that COS-treated cells induced apoptosis. The 
inhibition effects on the growth of hepatoma cells by COS might be related to apoptosis. The Bcl-2 protein was a potent 
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anti-apoptotic protein (Vaux et al., 1988; Berard et al., 2004) and Caspase-3 was a key enzyme apoptotic cascade in 
mammals (Corbiere et al., 2004; Nakamura et al., 2004; Tsujimoto et al., 2000). Insight into molecular mechanisms 
showed that Bcl-2 expression was decreased and Caspase-3 was increased in hepatoma cells following 24 h COS 
treatment. It is suggested that COS might induce apoptosis by up-regulating expression of Bcl-2 and down-regulating 
expression of Caspase-3.  
 
Conclusion 
 
 In conclusion, our data is the first one to indicate that COS could inhibit the growth of   hepatoma cells. 
Furthermore, COS can induce apoptosis which was related to the expression of down-regulated Bcl-2 and up-regulated 
Casepase-3. Therefore, we believed that the COS described in this study has potential to be developed as novel 
anti-cancer drug for hepatoma patients.  
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